COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms
A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.
You may also be interested in...
The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.
Canada’s R&D drug industry says it approached the court as a “necessary step,” given the significant impact of the pricing reforms.
Long awaited changes to Canada’s Patented Medicines Regulations have been announced, but companies will have to wait for new guidelines from the pricing watchdog to better understand how they will be implemented.